Risk Classification of Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin

Area of Science:

• Oncology
• Medical Science

Background:

• Enfortumab vedotin (EV) is a key treatment for advanced urothelial carcinoma (UC) post-platinum chemotherapy and immunotherapy.
• Limited data exists on prognostic factors and risk stratification for patients receiving EV.
• Identifying predictive factors is crucial for optimizing treatment strategies.

Purpose of the Study:

• To identify clinical prognostic factors for advanced UC patients treated with EV.
• To develop and validate a novel risk classification model based on these factors.

Main Methods:

• A multicenter retrospective study of advanced UC patients treated with EV.
• Assessment of progression-free survival (PFS) and overall survival (OS).
• Investigation of prognostic factors and validation of a risk classification model.

Main Results:

• Median PFS was 7.1 months and median OS was 16.3 months.
• Elevated C-reactive protein (CRP ≥0.5 mg/dl) and hypercalcemia (>10.2 mg/dl) were significant negative prognostic factors for both PFS and OS.
• A three-group risk classification model demonstrated significant differences in PFS and OS (c-indices: PFS 0.766, OS 0.800).

Conclusions:

• The developed risk classification model incorporating CRP and hypercalcemia effectively predicts outcomes in advanced UC patients treated with EV.
• This model aids in stratifying patients and anticipating treatment response.